KOSDAQBiotech & Pharma153710

Optipharm

₩4,450▼ 0.67%2026-10-02 close

Market Cap

₩66B

Turnover

₩45,811,920

Volume

10,000 shares

Shares out.

14.7M

PER

—

PBR

2.9×

EPS

-₩126

Dividend Yield

0.00%

PER, EPS, PBR and BPS are calculated in-house from the last 4 quarters (2025Q3–2026Q2) · Dividend yield is based on ₩0 per share · Prices as of the 2026-10-02 close

Report overview

FMD Vaccine Localization Nears, Profitability Still Pending

Optipharm, the domestic leader in animal disease diagnostics and a frontrunner in xenotransplantation, has entered the final stage of localizing a foot-and-mouth disease vaccine, but four consecutive years of operating losses mean the new business pipelines have yet to show up in actual earnings.

1
Revenue rose for four straight years from KRW 16.01 billion in 2022 to KRW 22.34 billion in 2025, but operating losses persisted throughout the period.
2
In Q2 2026, revenue reached KRW 6.59 billion with an operating loss of KRW 0.21 billion, the smallest loss among the last five quarters.
3
A CDMO agreement and clinical trial plan approval for a domestic foot-and-mouth disease (FMD) vaccine mark the final step toward localizing a market that has relied entirely on imports for about two decades.
4
Xenotransplantation research using the transgenic minipig 'MediPig' has produced preclinical data including a 180-day survival record in kidney-transplanted monkeys, backed by multiple government-funded projects.
5
The CEO purchased shares on the open market in January 2026, yet the company pays no dividend, reflecting a gap between ownership signaling and shareholder return policy.

Business structure

Founded in 2000, Optipharm is a biotech company specializing in animal disease diagnostics and animal pharmaceuticals, with its diagnostics business holding a domestic market share of over 60% by revenue, maintaining the industry's top position.

This business is built on infrastructure designated by the Animal and Plant Quarantine Agency (APQA) as a disease diagnosis institution capable of handling legally designated infectious diseases.

The second pillar is the animal pharmaceuticals and bacteriophage business, targeting the antibiotic-alternative feed additive market.

The company signaled its intent to enter the human pharmaceutical market by changing its English name from 'farm' to 'pharmaceutical' in 2018, and has since developed xenotransplantation, virus-like particle (VLP) vaccines, and human diagnostic kits as new growth businesses.

The xenotransplantation unit uses the gene-edited transgenic minipig 'MediPig' to research transplantation of hearts, kidneys, and pancreatic islets, and only four companies worldwide are known to possess such transgenic pigs.

The VLP vaccine technology extends beyond animal vaccines to human papillomavirus (HPV) vaccine development as well as FMD and hand-foot-mouth disease vaccine programs. Its customer base is diversified across livestock operators, veterinary clinics, and research institutions and university-affiliated hospitals.

While Optipharm holds a dominant position in animal diagnostics, it competes with domestic rivals such as Genenbio in the xenotransplantation field, and in the FMD vaccine segment its main competitor is the imported vaccine from Argentina's Biogenesis Bago, which has held roughly 60% of the domestic market.

Earnings trend

Quarterly revenue · Operating profit

₩5.8B-₩400M25Q2₩5.7B-₩500M25Q3₩6B-₩300M25Q4₩5.4B-₩700M26Q1₩6.6B-₩200M26Q2

RevenueOperating profit

Annual revenue · Operating profit

₩16B-₩3.4B2022₩17.4B-₩2.6B2023₩19.6B-₩2.5B2024₩22.3B-₩2.4B2025

RevenueOperating profit

Quarterly results · Last 5 quarters
Quarter	Revenue	Operating profit	Op. margin
2025Q2	₩5.8B	-₩400M	−7.5%
2025Q3	₩5.7B	-₩500M	−9.2%
2025Q4	₩6B	-₩300M	−5.4%
2026Q1	₩5.4B	-₩700M	−13.5%
2026Q2	₩6.6B	-₩200M	−3.1%

Annual results
Year	Revenue	Operating profit	Net income (parent)	Op. margin	ROE	Debt-to-equity
2022	₩16B	-₩3.4B	-₩2B	−21.1%	−7.0%	42.0%
2023	₩17.4B	-₩2.6B	-₩2.4B	−15.1%	−9.7%	56.2%
2024	₩19.6B	-₩2.5B	-₩2.4B	−12.5%	−8.6%	58.5%
2025	₩22.3B	-₩2.4B	-₩2.5B	−10.8%	−9.8%	60.5%

Consolidated basis (financial statements including subsidiaries) · Final figures from DART filings · Net income attributable to owners of the parent · Data as of 2026-08-22

Earnings analysis

Optipharm's annual revenue rose for four consecutive years, from KRW 16.01 billion in 2022 to KRW 17.37 billion in 2023, KRW 19.64 billion in 2024, and KRW 22.34 billion in 2025.

Operating losses, however, have continued over the same period, at KRW -3.38 billion (2022), KRW -2.63 billion (2023), KRW -2.45 billion (2024), and KRW -2.41 billion (2025). Still, the operating margin narrowed progressively from -21.1% in 2022 to -15.1% in 2023, -12.5% in 2024, and -10.8% in 2025.

Net loss attributable to owners widened from KRW -2.04 billion in 2022 to KRW -2.44 billion in 2023, then registered KRW -2.36 billion in 2024 and KRW -2.50 billion in 2025.

On a quarterly basis, revenue was KRW 5.68 billion with an operating loss of KRW 0.52 billion in Q3 2025, KRW 5.96 billion with a loss of KRW 0.32 billion in Q4 2025, then revenue fell to KRW 5.36 billion with the loss widening to KRW 0.72 billion in Q1 2026, before rebounding to KRW 6.59 billion in revenue with the operating loss narrowing to KRW 0.21 billion in Q2 2026, the smallest among the last five quarters.

Over the trailing four quarters (Q3 2025 through Q2 2026), cumulative revenue totaled roughly KRW 23.59 billion with a net loss attributable to owners of about KRW 1.86 billion.

Operating cash flow improved from KRW -2.43 billion in 2022 to KRW -1.72 billion in 2023 and KRW -0.60 billion in 2024, before worsening again to KRW -1.55 billion in 2025, while the debt ratio climbed steadily from 42.0% in 2022 to 60.5% in 2025, indicating a gradually increasing financial burden.

Overall, revenue growth and signs of margin improvement are visible simultaneously, but an outright swing to profitability has not yet been confirmed.

Industry analysis

The animal disease diagnostics and pharmaceuticals market shows stable demand amid livestock industry restructuring and tightening quarantine regulations, and Optipharm maintains a dominant position with over 60% market share by revenue in this segment.

In contrast, the domestic FMD vaccine market is estimated at roughly KRW 100 billion annually but has relied entirely on imports, meaning that successful localization could displace a meaningful share of existing imported vaccines.

The xenotransplantation field is an early-stage growth market drawing global attention after the U.S.

Food and Drug Administration (FDA) formally approved clinical trials for transplanting animal organs into humans, with Optipharm and Genenbio competing domestically on transgenic-pig-based solid organs and islet transplantation, respectively.

Still, the global longevity record for xenogeneic kidney transplantation stands at 499 days, set by a U.S. research team in 2019, indicating a continuing gap between domestic players, including Optipharm, and the global frontier.

The human VLP vaccine market, including hand-foot-mouth disease vaccines, remains an untapped area domestically with no commercialized product yet, though the broader market is growing across Asia.

Overall, Optipharm's core animal diagnostics and pharmaceutical business sits in a mature industry, while its xenotransplantation and human vaccine ventures remain in an early, pre-commercialization research stage.

Outlook

In December 2025, Optipharm signed a contract development and manufacturing organization (CDMO) agreement with ChoongAng Vaccine Laboratories for supplying a domestic K-FMD vaccine, under which Optipharm handles sales while ChoongAng Vaccine Laboratories handles production, with plans to focus first on the domestic market before pursuing expansion into Southeast Asian markets such as Vietnam and Indonesia.

According to a May 2026 report, Optipharm received approval for its FMD vaccine clinical trial plan from the Animal and Plant Quarantine Agency (APQA) and confirmed in preclinical testing a protective effect exceeding the vaccine assessment standard.

As of December 2025, the company stated its goal of completing clinical trials and the product approval process by the end of 2026 to begin full-scale sales from 2027, targeting roughly 30% of the domestic market in the first year of sales.

In the xenotransplantation segment, a five-year, KRW 38 billion government-led research project selected in 2023 is scheduled to compile preclinical data during 2026-2027 before seeking IND approval to enter clinical research, making the next one to two years a key period for gauging the actual transition to clinical trials.

In May 2026, Optipharm was also selected to lead a government-funded hand-foot-mouth disease vaccine project under the Vaccine Industry Technology Development Center, backed by the Ministry of Health and Welfare, committing KRW 1.95 billion over two years and eight months to preclinical research with a goal of filing an investigational new drug (IND) application by the end of 2028, adding a separate longer-term pipeline.

With multiple pipelines advancing simultaneously, adherence to each program's regulatory timeline stands out as a key variable that could influence future earnings and valuation assessments.

Valuation

PER

—

PBR

2.9×

ROE

-7.4%

EPS

-₩126

BPS

₩1,669

Dividend per share

₩0

Having recorded net losses over multiple years including the trailing four quarters, Optipharm sits in a structure where a conventional price-to-earnings (PER) calculation is difficult to apply.

Its price-to-book ratio tends to trade at a premium relative to net asset value, which can be interpreted as partly reflecting market expectations for the commercialization of new pipelines such as the FMD vaccine and xenotransplantation.

Dividends have not been paid in the most recent fiscal years, limiting the appeal from a dividend yield perspective.

On the earnings side, the operating margin has been negative for four consecutive years but has shown a gradual improving trend, leaving the pace of any further loss reduction or eventual swing to profitability as a variable that could influence how the market assesses valuation going forward.

Whether the new businesses' regulatory approval and commercialization timelines proceed as planned may also shape how the market views the multiple applied to net asset value.

PER, EPS, PBR and BPS are all calculated in-house (the same method as Naver and Toss) · Dividend yield = cash dividend per share from DART filings (supplemented by KRX) ÷ current price · As of 2026-08-22

Bull factors

Entering the Final Stage of FMD Vaccine Localization

Optipharm has reached the final stage of localizing the roughly KRW 100 billion domestic FMD vaccine market, which has relied entirely on imports for about two decades, by receiving clinical trial plan approval.

The CDMO agreement with ChoongAng Vaccine Laboratories, dividing sales and production roles, is seen as strengthening execution capability toward commercialization. The company has stated a goal of capturing about 30% of the market in the first year of sales.

This remains a planning-stage target, however, and actual product approval and market penetration speed still need to be observed.

Accumulated Xenotransplantation Preclinical Data and Multiple Government Projects

Kidney transplant research using the transgenic minipig 'MediPig' achieved a domestic record of 180-day survival in a monkey recipient, marking progress in preclinical data accumulation. Only four companies worldwide are known to possess such transgenic pigs, indicating a technical entry barrier.

The company has secured multiple government-funded projects, including a KRW 38 billion xenotransplantation program and a KRW 18.8 billion xenogeneic blood project, supporting the sustainability of its research and development. Still, actual clinical entry and commercialization remain years away at this early stage.

Revenue Growth Accompanied by Signs of Narrowing Losses

Revenue grew for four consecutive years from 2022 through 2025, reaching KRW 22.34 billion, while the operating margin narrowed progressively from -21.1% to -10.8%. In Q2 2026, revenue reached KRW 6.59 billion with an operating loss of KRW 0.21 billion, the smallest loss among the last five quarters.

This suggests both top-line expansion and cost control are progressing simultaneously. However, given notable quarterly volatility, such as the widened loss in Q1 2026, sustained confirmation over additional quarters is still needed.

Bear factors

Four Straight Years of Operating Losses and Weak Cash Generation

Optipharm recorded both operating losses and net losses attributable to owners in all four years from 2022 through 2025. Operating cash flow also remained consistently negative over the period, worsening to KRW -1.55 billion in 2025 compared with the prior year.

The debt ratio rose from 42.0% in 2022 to 60.5% in 2025, indicating gradually shrinking financial headroom. This loss structure could persist until new businesses begin contributing meaningfully to earnings.

Uncertainty Around New Business Commercialization Timing

While the FMD vaccine has received clinical trial plan approval, the procedures leading to product approval and the pace of market penetration remain unconfirmed.

Entry into clinical trials for the xenotransplantation segment depends on the 2026-2027 schedule of the government-funded project, and whether IND approval is actually granted remains to be seen.

The hand-foot-mouth disease vaccine is a long-term project targeting an IND filing by the end of 2028, implying commercialization is still a considerable way off. With multiple pipelines progressing simultaneously, delays in any one program could affect the company's overall growth narrative.

Thematic Supply-Demand Swings Typical of a Small-Cap Stock

Optipharm is a small-cap KOSDAQ stock, and its trading tends to be heavily influenced by thematic issues related to quarantine and livestock. Market commentary covering the sector has noted instances where livestock and quarantine-related stocks saw selling pressure emerge after short-term rallies.

This suggests share price movements can react sensitively to event-driven news independent of earnings fundamentals. Investors may need to distinguish such supply-demand characteristics from actual earnings data.

Risk factors

Regulatory and Approval Risk

Optipharm's FMD vaccine clinical trial plan previously received a request for supplementary materials from the Animal and Plant Quarantine Agency, so the possibility of further supplementation requests or schedule delays in the subsequent product approval process cannot be ruled out.

The xenotransplantation and human VLP vaccine pipelines must also pass through multi-stage regulatory procedures including IND approval and clinical trials, with risk of delays beyond expectations at each stage.

Any approval delay could directly affect the company's stated commercialization targets around the end of 2026 through 2027.

Financial Soundness and Funding Risk

With net losses continuing for four straight years, equity declined from KRW 29.01 billion in 2022 to KRW 25.40 billion in 2025, while the debt ratio rose from 42.0% to 60.5% over the same period.

Operating cash flow was also negative in most years, meaning internal cash generation alone is insufficient to cover research and development spending. If investment in new businesses and losses continue, additional external funding may become necessary, which is a variable that could affect shareholder value.

Competitive Risk

In the FMD vaccine segment, the imported vaccine from Argentina's Biogenesis Bago holds a firmly established position with about 60% of the domestic market, meaning market recapture could take time even after localization.

In xenotransplantation, domestic rival Genenbio has received phase 1 clinical trial approval for xenogeneic islet transplantation, indicating existing competition, and a gap remains between domestic players and the global leading group when compared to the 499-day global record for xenogeneic kidney transplant survival. This competitive landscape could affect the pace at which Optipharm's new businesses establish market position.

What to watch next

Mid-November 2026
Check whether the Q3 2026 earnings release and IR maintain the improving revenue and operating loss trend seen in Q2.
Q4 2026
This is the point to check whether the FMD vaccine's clinical trial and product approval process are completed as the company targeted, and whether the 2027 commercialization goal remains feasible.
Second half of 2026 through 2027
Monitor whether the second phase of the government-funded xenotransplantation project leads to an actual IND application and entry into clinical research.
Q4 2026
Check whether domestic FMD vaccine sales begin under the CDMO framework with ChoongAng Vaccine Laboratories, and how discussions on Southeast Asian export progress.
From 2027 onward
Continue tracking interim progress on the hand-foot-mouth disease vaccine preclinical research (targeting an IND filing by the end of 2028) and any additional government project wins.

Overall view

Optipharm has maintained stable dominance in the animal disease diagnostics business, growing revenue for four consecutive years, but operating and net losses over the same period mean the company has not yet offset the burden of new business investment with actual earnings.

The FMD vaccine has advanced to the final stage of localization with clinical trial plan approval, while the xenotransplantation segment has built a technical foundation through preclinical data, including a 180-day kidney transplant survival record in monkeys, and multiple government-funded projects.

However, both pipelines still face the next steps of product approval and clinical entry, so the timing of actual commercialization and revenue contribution remains unconfirmed.

The recent quarter's (Q2 2026) revenue growth and narrower loss are positive signals, but quarterly volatility is also evident, as seen in the widened loss of the preceding quarter (Q1 2026).

On the financial side, a rising debt ratio and persistently negative operating cash flow highlight financial soundness management as an important task while new business investment continues.

Investors may want to watch the FMD vaccine's product approval timeline, whether the xenotransplantation program enters clinical trials, and whether quarterly earnings improvement proves sustainable.

Sources

Korea Exchange (KRX) — Prices · Market Cap · Volume
FSS electronic disclosure system (DART) — Financial statements · Dividend filings

Show 18 more articles and sources

Report written 2026-09-05 · Data as of 2026-09-04

This content is AI analysis of market data and web search results, provided for information only. It is not a solicitation or recommendation to invest. Investment decisions and their consequences are the investor's own responsibility. Data may be delayed or contain errors.